Biological E. Limited — Vaccine Exporter Profile
Indian Pharmaceutical Exporter · #2 for Vaccine · $60.9M export value · DGFT Verified
Biological E. Limited is the #2 Indian exporter of Vaccine with $60.9M in export value and 859 verified shipments. Biological E. Limited holds a 4.1% market share in Vaccine exports across 104 countries. The company exports 5 pharmaceutical products worth $80.3M across 3 therapeutic categories.
Biological E. Limited — Vaccine Export Profile: Buyers & Destinations
Where Does Biological E. Limited Export Vaccine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PAKISTAN | $9.7M | 210 | 21.5% |
| BANGLADESH | $5.5M | 114 | 12.4% |
| NIGERIA | $2.6M | 60 | 5.8% |
| ETHIOPIA | $1.9M | 39 | 4.2% |
| NEPAL | $1.5M | 77 | 3.4% |
| TANZANIA | $1.0M | 38 | 2.2% |
| COLOMBIA | $995.1K | 25 | 2.2% |
| AFGHANISTAN | $850.0K | 17 | 1.9% |
| SUDAN | $829.1K | 17 | 1.8% |
| BURKINA FASO | $805.9K | 22 | 1.8% |
Biological E. Limited exports Vaccine to 128 countries. The largest destination is PAKISTAN accounting for 21.5% of Biological E. Limited's Vaccine shipments, followed by BANGLADESH (12.4%) and NIGERIA (5.8%). These destinations reflect Biological E. Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Vaccine from Biological E. Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| D.G. CENTRAL MEDICAL STORES DEPT | BANGLADESH | $2.7M | 54 |
| MINISTRY OF HEALTH | LAO PEOPLE'S DEMOCRATIC REPUBLIC | $2.2M | 50 |
| EXPANDED PROGRAMME ON IMMUNIZATION | PAKISTAN | $2.0M | 40 |
| NATIONAL PRIMARY HEALTH CARE | NIGERIA | $1.6M | 32 |
| EXPANDED PROGRAM ON IMMUNIZATION | PAKISTAN | $1.5M | 30 |
| D.G.CENTRAL MEDICAL STORES DEPT | BANGLADESH | $1.4M | 28 |
| AMSON VACCINES AND PHARMA PRIVATE LIMITED | PAKISTAN | $1.0M | 25 |
| MINISTERE DE LA SANTE | MOROCCO | $850.0K | 17 |
| AMSON VACCINES AND PHARMA PVT LTD., | PAKISTAN | $748.9K | 16 |
| PERMANENT SECRETARY | TANZANIA | $700.0K | 14 |
Biological E. Limited supplies Vaccine to 350 buyers globally. The largest buyer is D.G. CENTRAL MEDICAL STORES DEPT (BANGLADESH), followed by MINISTRY OF HEALTH (LAO PEOPLE'S DEMOCRATIC REPUBLIC) and EXPANDED PROGRAMME ON IMMUNIZATION (PAKISTAN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Vaccine Export Value and How Much Does Biological E. Limited Contribute?
India exported $313.3M worth of Vaccine through 14,355 shipments from 325 suppliers to 192 countries, serving 2,202 buyers globally. Biological E. Limited contributes $60.9M to this total, accounting for 4.1% of India's Vaccine exports. Biological E. Limited ships Vaccine to 128 countries through 350 buyers.
What Is the Average Shipment Value for Biological E. Limited's Vaccine Exports?
Biological E. Limited's average Vaccine shipment value is $70.9K per consignment, based on 859 shipments totaling $60.9M. The largest destination is PAKISTAN (21.5% of Biological E. Limited's Vaccine exports).
How Does Biological E. Limited Compare to Other Indian Vaccine Exporters?
Biological E. Limited ranks #2 among 325 Indian Vaccine exporters with a 4.1% market share. The top 3 exporters are SERUM INSTITUTE OF INDIA PRIVATE LIMITED ($161.3M), BIOLOGICAL E. LIMITED ($43.0M), BHARAT BIOTECH INTERNATIONAL LIMITED ($30.4M). Biological E. Limited processed 859 shipments to 104 destination countries.
What Vaccine Formulations Does Biological E. Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DTP-HEPB-HIB (PENTAVALENT VACCINE) FULLY | $4.6M | 100 |
| DTP-HEPB-HIB (PENTAVALENT VACCINE) DTP-HEPB-HIB (PENTAVALENT VACCINE) FULLY LIQUID COMBINATION VACCINE,SINGLE DOSE | $2.6M | 58 |
| MR VACCINE MEASLES AND RUBELLA VACCINE C | $1.5M | 31 |
| TYPHOID CONJUGATE VACCINE MONOVALENT 5 DOSE 2.5ML VIAL WITH VACCINE VIAL MONITOR(VVM) | $1.5M | 32 |
| DTP-HEPB-HIB (PENTAVALENT VACCINE) FULLYLIQUID COMBINATION VACCINE 10 DOSE VIALPAEDIARIC DOSE DIPHTHERIA,TETANUS,** | $1.3M | 28 |
| S359348 MR VACCINE MEASLES AND RUBELLA | $1.3M | 27 |
| DTP-HEPB-HIB (PENTAVALENT VACCINE) FULLYLIQUID COMBINATION VACCINE, 10 DOSE (5ML) VIAL | $1.1M | 22 |
| MR VACCINE MEASLES AND RUBELLA VACCINE COMBINED VIAL OF 5 DOSES WITH DILUENT. WITH VACCINE VIAL MONITOR (VVM) | $1.1M | 22 |
| DTP-HEPB-HIB (PENTAVALENT VACCINE) DTP-H | $1.0M | 21 |
| DTP-HEPB-HIB (PENTAVALENT VACCINE) FULLYLIQUID COMBINATION VACCINE,SINGLE DOSEVIAL(0.5ML) VIAL,PEDIATRIC DOSE ** | $900.0K | 18 |
Biological E. Limited exports 411 distinct Vaccine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DTP-HEPB-HIB (PENTAVALENT VACCINE) FULLY with 100 shipments worth $4.6M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Vaccine to Key Markets
What Biological E. Limited must comply with to export Vaccine to its top destination countries
Nigeria — NAFDAC
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Biological E. Limited Compare to Nearest Vaccine Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | SERUM INSTITUTE OF INDIA PRIVATE LIMITED | $161.3M | 3,225 | 164 | $50.0K |
| 2 | BIOLOGICAL E. LIMITED ★ | $43.0M | 859 | 104 | $50.0K |
| 3 | BHARAT BIOTECH INTERNATIONAL LIMITED | $30.4M | 609 | 77 | $50.0K |
| 6 | INDIAN IMMUNOLOGICALS LIMITED | $20.1M | 403 | 34 | $50.0K |
Biological E. Limited ranks #2 among 325 Indian Vaccine exporters. Average shipment value of $50.0K compared to the market average of $964.0K. The closest competitors by value are SERUM INSTITUTE OF INDIA PRIVATE LIMITED and BHARAT BIOTECH INTERNATIONAL LIMITED.
Which Indian Ports Ship Vaccine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 3,489 | 24.3% |
| SAHAR AIR | 2,995 | 20.9% |
| Bombay Air | 855 | 6.0% |
| HYDERABAD ACC (INHYD4) | 839 | 5.8% |
| HYDERABAD AIR | 805 | 5.6% |
| DELHI AIR CARGO ACC (INDEL4) | 752 | 5.2% |
| DELHI AIR | 581 | 4.0% |
| AHEMDABAD AIR ACC (INAMD4) | 373 | 2.6% |
What Other Other Products Does Biological E. Limited Export?
Biological E. Limited also exports these other products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Biological E. Limited's Vaccine Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like BE. The Israel-Iran conflict has disrupted Red Sea shipping routes, leading to increased freight charges and potential losses estimated between ₹2,500 crore and ₹5,000 crore for the Indian pharma industry in March 2026. (fortuneindia.com) These disruptions can elongate lead times and elevate cold-chain failure risks, particularly for temperature-sensitive products like vaccines. (pharmaceuticalcommerce.com)
Conversely, U.S.-China trade tensions have prompted the U.S. to seek alternative suppliers, potentially benefiting Indian exporters. However, the imposition of tariffs on pharmaceutical imports by the U.S. in August 2025 posed challenges, with Indian exporters facing increased costs and competitive disadvantages. (apnews.com) The subsequent withdrawal of tariffs on generic drugs in October 2025 provided some relief, yet the episode underscores the volatility of trade policies and the need for exporters to remain agile. (medboundtimes.com)
In the European Union, compliance with the Falsified Medicines Directive requires stringent serialization and traceability measures. For companies like BE, ensuring adherence to these regulations is crucial to maintain market access and uphold their reputation for quality.
Biological E. Limited — Regulatory Compliance & Quality Standards
Regulatory compliance remains a cornerstone for Indian pharmaceutical exporters. The U.S. FDA has intensified inspections, with over 200 conducted in 2023 and plans to increase this number in 2024. (fact.net.in) Instances of quality issues and FDA warnings have previously affected the reputation of Indian pharma exports. (svhealthcare.in) For BE, maintaining compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP) is imperative to sustain and expand its export footprint.
The company's recent WHO pre-qualification for nOPV2 reflects its commitment to quality and regulatory excellence. However, the broader industry faces challenges related to counterfeit drugs and quality concerns, which can impact India's reputation as a reliable supplier. (fact.net.in) Proactive measures, including robust quality assurance systems and transparent governance, are essential for BE to navigate this evolving landscape.
About Biological E. Limited
Biological E. Limited exports 5 products worth $80.3M. Beyond Vaccine, top products include Enoxaparin, Sodium, Antitoxin, Heparin. View the complete Biological E. Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Vaccine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Vaccine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Biological E. Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 1,218 individual customs records matching Biological E. Limited exporting Vaccine, covering 411 formulations to 128 countries via 350 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 192+ countries, 2,202+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Vaccine Export Data from Biological E. Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Biological E. Limited's Vaccine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Biological E. Limited
Full Company Profile →
5 products · $80.3M total trade · 3 categories
Vaccine Stats
Company Overview
Top Products by Biological E. Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Biological E. Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Vaccine. For current shipment-level data, contact TransData Nexus.